tetano
Editor, Senior Moderator
J Obstet Gynaecol Res
. 2024 Nov 12.
doi: 10.1111/jog.16150. Online ahead of print. Possible rapid reduction of anti-RBD antibody titre after SARS-CoV-2 mRNA vaccination in pregnant women: Multicentre prospective study
Mamiko Ohta[SUP] 1 [/SUP], Kaoru Kawasaki[SUP] 1 [/SUP], Rumiko Yamamoto[SUP] 2 [/SUP], Keisuke Ishii[SUP] 2 [/SUP], Kazutoshi Nakano[SUP] 3 [/SUP], Shinobu Akada[SUP] 3 [/SUP], Kunihiko Doh[SUP] 4 [/SUP], Masao Shimaoka[SUP] 5 [/SUP], Hiroshi Ota[SUP] 6 [/SUP], Kaori Moriuchi[SUP] 1 [/SUP], Reona Shiro[SUP] 1 [/SUP], Yoshie Yo[SUP] 1 [/SUP], Koichiro Yoshida[SUP] 7 [/SUP], Yuji Tohda[SUP] 8 [/SUP], Noriomi Matsumura[SUP] 1 [/SUP]
Affiliations
Aim: Pregnant women are at increased risk for severe illness associated with coronavirus disease 2019 (COVID-19) compared to nonpregnant women. The aim of this multicenter prospective study was to assess the current COVID-19 vaccination status of pregnant women in the southern Osaka district and to compare their antibody titers with those of nonpregnant women.
Methods: Serum antibody titers of anti-NCP antibodies (antibodies against the SARS-CoV-2 nucleocapsid) and anti-RBD antibodies (the receptor binding domain of the S1 subunit of the spike protein) were evaluated in 753 pregnant women at 34-35 weeks of gestation from October 2021 to March 2022. Anti-RBD antibody titre was also investigated in 1003 health care workers at Kindai University hospital 3 and 6 months after a second dose of the vaccine from March 2021 to April 2021. 519 (68.9%) pregnant women were vaccinated during pregnancy, of whom 497 (95.8%) received two doses.
Results: The COVID-19 infection rate calculated from the number of pregnant women with a positive anti-NCP antibody titre or with confirmed diagnosis was 5.1% (12/234) in the unvaccinated and 3.5% (18/519) in the vaccinated. The estimated half-life calculated from anti-RBD antibody titers and the number of days between vaccination and antibody testing was 39.9 days. The antibody titre and half-life in pregnant women were significantly lower and shorter than in nonpregnant women aged 20-39 years (109.4 days).
Conclusion: Our study showed that pregnant women may have lower vaccine-acquired COVID-19 immunity than nonpregnant women.
Keywords: COVID‐19; antibodies; coronavirus disease 2019; pregnancy; vaccination.
. 2024 Nov 12.
doi: 10.1111/jog.16150. Online ahead of print. Possible rapid reduction of anti-RBD antibody titre after SARS-CoV-2 mRNA vaccination in pregnant women: Multicentre prospective study
Mamiko Ohta[SUP] 1 [/SUP], Kaoru Kawasaki[SUP] 1 [/SUP], Rumiko Yamamoto[SUP] 2 [/SUP], Keisuke Ishii[SUP] 2 [/SUP], Kazutoshi Nakano[SUP] 3 [/SUP], Shinobu Akada[SUP] 3 [/SUP], Kunihiko Doh[SUP] 4 [/SUP], Masao Shimaoka[SUP] 5 [/SUP], Hiroshi Ota[SUP] 6 [/SUP], Kaori Moriuchi[SUP] 1 [/SUP], Reona Shiro[SUP] 1 [/SUP], Yoshie Yo[SUP] 1 [/SUP], Koichiro Yoshida[SUP] 7 [/SUP], Yuji Tohda[SUP] 8 [/SUP], Noriomi Matsumura[SUP] 1 [/SUP]
Affiliations
- PMID: 39530282
- DOI: 10.1111/jog.16150
Aim: Pregnant women are at increased risk for severe illness associated with coronavirus disease 2019 (COVID-19) compared to nonpregnant women. The aim of this multicenter prospective study was to assess the current COVID-19 vaccination status of pregnant women in the southern Osaka district and to compare their antibody titers with those of nonpregnant women.
Methods: Serum antibody titers of anti-NCP antibodies (antibodies against the SARS-CoV-2 nucleocapsid) and anti-RBD antibodies (the receptor binding domain of the S1 subunit of the spike protein) were evaluated in 753 pregnant women at 34-35 weeks of gestation from October 2021 to March 2022. Anti-RBD antibody titre was also investigated in 1003 health care workers at Kindai University hospital 3 and 6 months after a second dose of the vaccine from March 2021 to April 2021. 519 (68.9%) pregnant women were vaccinated during pregnancy, of whom 497 (95.8%) received two doses.
Results: The COVID-19 infection rate calculated from the number of pregnant women with a positive anti-NCP antibody titre or with confirmed diagnosis was 5.1% (12/234) in the unvaccinated and 3.5% (18/519) in the vaccinated. The estimated half-life calculated from anti-RBD antibody titers and the number of days between vaccination and antibody testing was 39.9 days. The antibody titre and half-life in pregnant women were significantly lower and shorter than in nonpregnant women aged 20-39 years (109.4 days).
Conclusion: Our study showed that pregnant women may have lower vaccine-acquired COVID-19 immunity than nonpregnant women.
Keywords: COVID‐19; antibodies; coronavirus disease 2019; pregnancy; vaccination.